Glyburide
Sulfonylureas
Sold as Amglidia
- Drug class
- Sulfonylureas
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 4
- Products on record
- 17
- FDA reports (12 mo)
- 187
Overview
Glyburide is an active pharmaceutical ingredient in the Sulfonylureas group (A10BB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 10 | May 29, 2026 |
| CA Canada | Health Canada | 5 | March 22, 2025 |
| US United States | FDA | 1 | January 28, 2025 |
| EU European Union | EMA | 1 | May 11, 2026 |
GBUnited Kingdom· MHRA
10 products
Uses
AMGLIDIA is indicated for the treatment of neonatal diabetes mellitus, for use in newborns, infants and children. Sulphonylureas like AMGLIDIA have been shown to be effective in patients with mutations in the genes coding for the β-cell ATP-sensitive potassium channel and chromosome 6q24-related transient neonatal diabetes mellitus.
How to take
CACanada· Health Canada
5 products
Uses
AND CLINICAL USE ........................................................................................... 3 CONTRAINDICATIONS ..............................................................................................................
3 WARNINGS AND PRECAUTIONS ............................................................................................. 4 ADVERSE REACTIONS..............................................................................................................
7 DRUG INTERACTIONS .............................................................................................................. 9 DOSAGE AND ADMINISTRATION ...........................................................................................
13 OVERDOSAGE ......................................................................................................................... 15 ACTION AND CLINICAL PHARMACOLOGY ............................................................................
USUnited States· FDA
1 product
Uses
INDICATIONS AND USAGE
Glyburide tablets, USP is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
How to take
EUEuropean Union· EMA
1 product
Uses
AMGLIDIA is indicated for the treatment of neonatal diabetes mellitus, for use in newborns, infants and children. Sulphonylureas like AMGLIDIA have been shown to be effective in patients with mutations in the genes coding for the β-cell ATP-sensitive potassium channel and chromosome 6q24-related transient neonatal diabetes mellitus.
How to take
Drug interactions
Known interactions involving Glyburide. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 576. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB506870004 · revised March 20, 2026
- [2]Health Canada (DPD) · 01913654 · revised March 22, 2025
- [3]FDA DailyMed · 05341afe-5b7a-46… · revised January 28, 2025 [PDF]
- [4]European Medicines Agency · EMEA/H/C/004379 · revised May 11, 2026
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.